^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Kidrolase (L-asparaginase)

    Associations

    News

    Trials
    Company:
    Jazz, Merck (MSD)
    Drug class:
    Aspartate-ammonia ligase inhibitor, Amidohydrolase stimulant
    Related drugs:
    Associations

    News

    Trials
    4ms
    Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome (clinicaltrials.gov)
    P3, N=280, Active, not recruiting, Children's Oncology Group | Trial completion date: Jul 2025 --> Jun 2026
    Trial completion date
    |
    GATA1 (GATA Binding Protein 1)
    |
    cytarabine • etoposide IV • daunorubicin • mitoxantrone • mercaptopurine • Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) • thioguanine • Kidrolase (L-asparaginase) • Leunase (L-asparaginase) • Spectrila (asparaginase Escherichia coli) • Starasid (cytarabine ocfosfate)
    over1year
    Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome (clinicaltrials.gov)
    P3, N=280, Active, not recruiting, Children's Oncology Group | Trial completion date: Jun 2024 --> Jul 2025
    Trial completion date
    |
    GATA1 (GATA Binding Protein 1)
    |
    cytarabine • etoposide IV • daunorubicin • mitoxantrone • mercaptopurine • Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) • thioguanine • Kidrolase (L-asparaginase) • Leunase (L-asparaginase) • Spectrila (asparaginase Escherichia coli) • Starasid (cytarabine ocfosfate)
    over1year
    AALL0631: Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P3, N=218, Completed, Children's Oncology Group | Active, not recruiting --> Completed
    Trial completion
    |
    cytarabine • cyclophosphamide • etoposide IV • methotrexate • vincristine • daunorubicin • leucovorin calcium • Oncaspar liquid (pegaspargase) • lestaurtinib (CEP-701) • mercaptopurine • Hemady (dexamethasone tablets) • Kidrolase (L-asparaginase) • Leunase (L-asparaginase) • Neupogen (filgrastim) • Spectrila (asparaginase Escherichia coli) • Starasid (cytarabine ocfosfate)
    over1year
    AALL0434: Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma (clinicaltrials.gov)
    P3, N=1895, Active, not recruiting, National Cancer Institute (NCI)
    Trial completion date
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD8 (cluster of differentiation 8) • CD22 (CD22 Molecule) • CD34 (CD34 molecule) • CD5 (CD5 Molecule) • CD7 (CD7 Molecule) • CD2 (CD2 Molecule) • MPO (Myeloperoxidase)
    |
    CD22 expression
    |
    cytarabine • doxorubicin hydrochloride • cyclophosphamide • methotrexate • vincristine • daunorubicin • leucovorin calcium • Oncaspar liquid (pegaspargase) • nelarabine • mercaptopurine • thioguanine • Hemady (dexamethasone tablets) • Kidrolase (L-asparaginase) • Leunase (L-asparaginase) • Spectrila (asparaginase Escherichia coli) • Starasid (cytarabine ocfosfate) • dexamethasone injection
    over1year
    A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations (clinicaltrials.gov)
    P3, N=1400, Active, not recruiting, Children's Oncology Group | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    FLT3 (Fms-related tyrosine kinase 3)
    |
    Xospata (gilteritinib) • etoposide IV • methotrexate • Mylotarg (gemtuzumab ozogamicin) • Vyxeos (cytarabine/daunorubicin liposomal formulation) • mitoxantrone • Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) • Kidrolase (L-asparaginase) • Leunase (L-asparaginase) • Spectrila (asparaginase Escherichia coli) • Starasid (cytarabine ocfosfate) • dexrazoxane
    2years
    AALL0631: Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P3, N=218, Active, not recruiting, Children's Oncology Group | Trial completion date: Jul 2023 --> Jun 2024
    Trial completion date
    |
    FLT3 (Fms-related tyrosine kinase 3)
    |
    cytarabine • cyclophosphamide • etoposide IV • methotrexate • vincristine • daunorubicin • leucovorin calcium • Oncaspar liquid (pegaspargase) • lestaurtinib (CEP-701) • mercaptopurine • Hemady (dexamethasone tablets) • Kidrolase (L-asparaginase) • Leunase (L-asparaginase) • Neupogen (filgrastim) • Spectrila (asparaginase Escherichia coli) • Starasid (cytarabine ocfosfate)
    over2years
    AALL1331: Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P3, N=669, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jun 2023 --> Apr 2024
    Trial completion date
    |
    cytarabine • cyclophosphamide • Blincyto (blinatumomab) • etoposide IV • methotrexate • vincristine • mitoxantrone • leucovorin calcium • Oncaspar liquid (pegaspargase) • mercaptopurine • thioguanine • Hemady (dexamethasone tablets) • Kidrolase (L-asparaginase) • Leunase (L-asparaginase) • Spectrila (asparaginase Escherichia coli) • Starasid (cytarabine ocfosfate)
    almost4years
    ANTIMETABOLIC COOPERATIVITY WITH THE CLINICALLY-APPROVED L-ASPARAGINASE AND TYROSINE KINASE INHIBITORS TO ERADICATE CML STEM CELLS. (PubMed, Mol Metab)
    We investigated metabolic pathways responsible for CML surviving Imatinib exposure and its potential therapeutic utility to improve the efficiency of TKI against CML stem cells. The combination of TKI with L-asparaginase reactivated the intinsic apoptotic pathway leading to efficient CML cell death. Thus, targeting glutamine metabolism with the clinically-approved drug Kidrolase, in combination with TKI which suppresses glycolysis, represents an effective and widely applicable therapeutic strategy for eradicating CML stem cells.
    Clinical • Journal
    |
    ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • CD34 (CD34 molecule)
    |
    imatinib • Kidrolase (L-asparaginase)
    5years
    Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia (clinicaltrials.gov)
    P3, N=1070, Completed, Children's Oncology Group | Trial completion date: Aug 2013 --> Sep 2020
    Clinical • Trial completion date
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1)
    |
    cytarabine • etoposide IV • Mylotarg (gemtuzumab ozogamicin) • daunorubicin • mitoxantrone • Kidrolase (L-asparaginase)
    5years
    Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome (clinicaltrials.gov)
    P3, N=256, Recruiting, Children's Oncology Group | Trial primary completion date: Mar 2023 --> Jun 2023
    Clinical • Trial primary completion date
    |
    GATA1 (GATA Binding Protein 1)
    |
    cytarabine • etoposide IV • daunorubicin • mitoxantrone • mercaptopurine • thioguanine • Erwinase (erwinia asparaginase) • Kidrolase (L-asparaginase) • Spectrila (asparaginase Escherichia coli)
    5years
    A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations (clinicaltrials.gov)
    P3, N=1400, Recruiting, Children's Oncology Group | Trial completion date: Feb 2025 --> Sep 2027 | Trial primary completion date: Feb 2025 --> Sep 2027
    Clinical • Trial completion date • Trial primary completion date
    |
    FLT3 (Fms-related tyrosine kinase 3)
    |
    Xospata (gilteritinib) • etoposide IV • methotrexate • Mylotarg (gemtuzumab ozogamicin) • Vyxeos (cytarabine/daunorubicin liposomal formulation) • mitoxantrone • Erwinase (erwinia asparaginase) • Kidrolase (L-asparaginase) • Spectrila (asparaginase Escherichia coli) • dexrazoxane